BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38334668)

  • 1. Clinical Relevance and Interplay between miRNAs in Influencing Glioblastoma Multiforme Prognosis.
    Epistolio S; Dazio G; Zaed I; Sahnane N; Cipriani D; Polinelli F; Barizzi J; Spina P; Stefanini FM; Cerati M; Balbi S; Mazzucchelli L; Sessa F; Pesce GA; Reinert M; Cardia A; Marchi F; Frattini M
    Cells; 2024 Feb; 13(3):. PubMed ID: 38334668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity.
    Cardia A; Epistolio S; Zaed I; Sahnane N; Cerutti R; Cipriani D; Barizzi J; Spina P; Stefanini FM; Cerati M; Balbi S; Mazzucchelli L; Sessa F; Pesce GA; Reinert M; Frattini M; Marchi F
    J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
    Chen H; Li X; Li W; Zheng H
    J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
    Tezcan G; Tunca B; Bekar A; Preusser M; Berghoff AS; Egeli U; Cecener G; Ricken G; Budak F; Taskapılıoglu MO; Kocaeli H; Tolunay S
    Cell Mol Neurobiol; 2014 Jul; 34(5):679-92. PubMed ID: 24691539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
    Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
    Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma.
    Yin J; Zeng A; Zhang Z; Shi Z; Yan W; You Y
    EBioMedicine; 2019 Apr; 42():238-251. PubMed ID: 30917935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
    Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
    J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-181d associated with the methylation status of the MGMT gene in Glioblastoma multiforme cancer stem cells submitted to treatments with ionizing radiation and temozolomide.
    Lizarte Neto FS; Rodrigues AR; Trevisan FA; de Assis Cirino ML; Matias CCMS; Pereira-da-Silva G; Peria FM; Tirapelli DPDC; Carlotti CG
    Brain Res; 2019 Oct; 1720():146302. PubMed ID: 31226325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression.
    Zhang W; Zhang J; Hoadley K; Kushwaha D; Ramakrishnan V; Li S; Kang C; You Y; Jiang C; Song SW; Jiang T; Chen CC
    Neuro Oncol; 2012 Jun; 14(6):712-9. PubMed ID: 22570426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.
    Lakomy R; Sana J; Hankeova S; Fadrus P; Kren L; Lzicarova E; Svoboda M; Dolezelova H; Smrcka M; Vyzula R; Michalek J; Hajduch M; Slaby O
    Cancer Sci; 2011 Dec; 102(12):2186-90. PubMed ID: 21895872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
    Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
    Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F
    J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
    Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
    Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
    Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.
    Berthois Y; Delfino C; Metellus P; Fina F; Nanni-Metellus I; Al Aswy H; Pirisi V; Ouafik L; Boudouresque F
    Cancer Biol Ther; 2014 Jul; 15(7):938-50. PubMed ID: 24755707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.